As of 2025-11-07, the Intrinsic Value of Terns Pharmaceuticals Inc (TERN) is -5.25 USD. This TERN valuation is based on the model Peter Lynch Fair Value. With the current market price of 18.25 USD, the upside of Terns Pharmaceuticals Inc is -128.74%.
Based on its market price of 18.25 USD and our intrinsic valuation, Terns Pharmaceuticals Inc (TERN) is overvalued by 128.74%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -5.25 - -5.25 | -5.25 | -128.74% |
| P/E | (33.85) - (35.64) | (34.39) | -288.4% |
| DDM - Stable | (18.60) - (76.61) | (47.60) | -360.8% |
| DDM - Multi | (4.49) - (14.45) | (6.86) | -137.6% |
| Market Cap (mil) | 940.25 |
| Beta | 2.02 |
| Outstanding shares (mil) | 51.52 |
| Enterprise Value (mil) | 816.25 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.40% |
| Cost of Debt | 5.00% |
| WACC | 6.68% |